NOTCH1 and neoplasm: Our in vivo study clearly showed that overexpression of miR-221/222 significantly enhanced tumor growth, providing an evidence to target miR-221/222 as an upstream regulator of Notch1 signaling in regulating CSCs and achieving potential therapeutic effects on NSCLC.